NASDAQ:GNPX Genprex Q3 2025 Earnings Results & Report $1.45 -0.22 (-13.17%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$1.48 +0.03 (+1.72%) As of 11/20/2026 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Genprex beat analyst earnings expectations in its Q3 2025 results, released November 14, 2025. The company reported EPS of -$110.00 versus the -$275.00 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 14, 2025TimeBefore Market Opens Genprex EPS ResultsActual EPS-$110.00Consensus EPS -$275.00Beat/MissBeat by +$165.00One Year Ago EPSN/AGenprex Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsGenprex's next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Genprex Q3 2025 Earnings FAQ Did Genprex beat earnings estimates for Q3 2025? Genprex (NASDAQ:GNPX) reported earnings of -$110.00 per share for Q3 2025, beating the consensus estimate of -$275.00. The report was announced on Friday, November 14, 2025. When is Genprex's next earnings date? Genprex's next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Genprex on the company's earnings history page. Genprex Earnings HeadlinesGenprex Presents Preclinical Data Identifying TROP2 as a Potential Predictive Biomarker for Reqorsa® Gene Therapy in Lung CancerNovember 19 at 7:00 AM | prnewswire.comGenprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy SymposiumNovember 11, 2026 | prnewswire.comSeven bucks, yours for life: my Black Friday indicator dealBase Camp Trading's Thomas Wood is giving away his proprietary Snapback Indicator for just $7 this Black Friday. Others paid $500 for it. It's a one-time price with no recurring billing, and the indicator is yours for life. It shows when it's time to sell or go short, and when it makes sense to buy. Check it for a potential Snapback before your next trade.November 22 at 1:00 AM | Base Camp Trading (Ad)Genprex Reports Reqorsa Translational Analysis in Lung Cancer PatientsNovember 5, 2026 | tipranks.comGenprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated StressNovember 5, 2026 | prnewswire.comGenprex Identifies TROP2 Biomarker for Reqorsa Treatment ResponseNovember 4, 2026 | tipranks.comSee More Genprex Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Genprex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genprex and other key companies, straight to your email. Email Address About GenprexGenprex (NASDAQ:GNPX), Inc. is a clinical-stage gene therapy company developing treatments for cancer and diabetes. The company is based in Austin, Texas, and its work focuses on using genetic material to address diseases with significant unmet medical needs. Its lead cancer candidate, REQORSA (quaratusugene ozeplasmid), is an investigational, non-viral gene therapy designed to deliver the TUSC2 tumor-suppressor gene to cancer cells. Genprex has studied REQORSA in clinical trials for non-small cell lung cancer, including in combination with other cancer therapies. Genprex is also developing an investigational gene therapy program for diabetes. Its candidates remain in development, and the company’s therapies are not approved for commercial use.View Genprex ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/16 - 11/20Keysight Technologies: The Tollbooth on the Technology SuperhighwayGrowing Pains Versus Growth: Is BJ’s Wholesale Club a Buying Opportunity?Bargain Hunting: Why Off-Price Retail Is WinningZscaler Got a Boost From Palo Alto, But Now It Has to Deliver.If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.